Bangkok Lab and Cosmetic, or BLC, plans to launch three new products in the second half of 2026, comprising two herbal products and one new generic drug. The company is also preparing to begin system testing at its newly completed factory to unlock production capacity constraints and support future growth. Chief Executive Officer Suvit Ngamphuphan said the new plant will enter the system testing phase to fully drive the company into a new S-curve. For the second quarter of 2026, the company posted total sales and service revenue of 399.0 million baht, down 4.5 percent from the previous quarter and down 3.3 percent from the same period last year. However, the herbal product segment continued to stand out, generating revenue of 46.5 million baht, an increase of 8.0 million baht from the previous quarter and 16.10 million baht from the prior year, with the Plaivana brand in particular achieving 18 percent sales growth year-on-year. Net profit for the second quarter was 30.2 million baht, with net profit margin rising to 7.6 percent from 7.3 percent in the first quarter. Additionally, the board of directors meeting on August 10, 2026 approved an interim dividend payment of 0.05 baht per share, totaling 30 million baht, with the XD date set for August 21, 2026 and payment on September 9, 2026.
Bangkok Lab & Cosmetic PCLPlans to launch three new products and begin testing new plant systems to support growth.
